Breaking News From Pharma & Bio Ingredients
Treprostinil Controlled Pilot Study in JACC
Posted on 2007-02-09 14:24:00
Lung Rx Inc. (a subsidiary of United Therapeutics Corp) announced publication in The Journal of The American College of Cardiology (JACC) of the results of their randomized, controlled pilot studies of Treprostinil Sodium for Inhalation, a treatment they are developing for severe pulmonary arterial hypertension.
The JACC publication, entitled "Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension: Results From Randomized Controlled Pilot Studies," reports on the results of right heart catheterizations performed more than 120 patients in three separate clinical trials.
Lung Rx is in the process of completing its confirmatory TRIUMPH-1 (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) study, a 12-week, double-blind, randomized, placebo-controlled study of VIVETA in NYHA Class III and IV patients with severe pulmonary arterial hypertension that is being conducted in the United States and Europe.
Subscribe via RSS
